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Introduction
The precise roles of IL-la and IL-Il# in normal physiology in vivo or in pathophysiology ofdisease remain unclear. Because ofthe ubiquitous, and somewhat nonspecific, nature ofproduction and effects of IL-I a and IL-1# in vitro, the importance of these molecules in vivo has been questioned. A new member of the IL-I family has recently been described. IL-I receptor antagonist (IL-lra)' is structurally related to IL-la and IL-lIB, but binds to IL-I receptors on various target cells without inducing any discernible biological responses. IL-Ira represents the first described naturally occurring cytokine or hormone-like molecule that functions as a specific receptor antagonist.
This article will review recent information about IL-lra, including its discovery and biochemical characterization, production, in vitro properties, and in vivo effects. A further objective is to point out how knowledge about IL-Ira may not only provide answers about the relevance of IL-i a and IL-1 f in vivo, but also may introduce new concepts about the function of these other members of the IL-I family. The reader is referred to three recent more brief reviews on IL-lra (1-3).
IL-I inhibitors and discovery ofIL-Ira
IL-1 inhibitory bioactivity has been described by many laboratories over the past 10-15 years, both in cultured cell supernatants and in human body fluids (reviewed in [4] [5] [6] . Some of these "IL-1 inhibitors" may have represented proteins that bound to IL-I in solution or other molecules that interfered nonspecifically with bioassays for IL-I. However, the nature and mechanisms of action of most of these IL-I inhibitors remained undetermined.
The molecule now known as IL-1ra was first reported in 1985 as an IL-I inhibitory bioactivity of22-25 kD in the supernatants of human monocytes cultured on adherent IgG (7). Dayer and colleagues independently reported studies on an IL-inhibitor of similar size in the urine of patients with fever leukin 1 receptor antagonist.
or myelomonocytic leukemia (8) . Seckinger et al. (9) established that the 22-kD inhibitor semipurified from urine specifically blocked binding of 123I-IL-la to IL-I receptors on the murine thymoma cell line EL4-6. 1. Subsequent studies showed that the monocyte-derived molecule also functioned as a specific receptor antagonist of IL-1 (5) . Additional effects of IL-I that are blocked by native IL-I ra are summarized in Table I . In all of these studies, IL-Ira alone failed to exhibit any agonist properties.
Purification, sequencing, cloning, and expression ofIL-Ira Any uncertainties regarding the existence ofa specific receptor antagonist ofIL-I were resolved by the purification ofthis molecule from IgG-induced monocyte supernatants by Hannum et al. (14) . Using a combination of anion exchange, gel filtration, and reverse-phase HPLC, three species of native IL-Ira were identified. The monocyte-derived IL-Ira exhibited two species of 22 kD and a smaller species of 18 kD (14) . The two larger forms appeared to be glycosylation derivatives of the 18-kD form, as evidenced by reduction in their sizes to 18 kD with N-glycanase digestion. All three forms of purified native IL-Ira possessed equivalent IL-I receptor binding activity per weight, indicating that the N-linked sugar was not essential for this activity ( 14) .
Eisenberg et al. cloned IL-I ra cDNA's from a human monocyte library (15) . Characteristics of a 1.8-kb IL-Ira cDNA and of the predicted protein are summarized in Table II . This IL-I ra cDNA was expressed in Escherichia coli with production of an 1 8-kD molecule that blocked IL-i-induced PGE2 production by fibroblasts (15) . The recombinant human IL-Ira inhibited in a dose-responsive fashion 1251-IL-la binding to EL4-6.1 murine thymoma cells (14) . Lastly, the recombinant IL-Ira failed to directly stimulate PGE2 production by human dermal fibroblasts (14) .
An identical IL-I receptor antagonist protein (termed IRAP) was subsequently purified from the supernatants of the human myelomonocytic cell line U937 after phorbol myristate acetate (PMA) differentiation and stimulation with granulocyte macrophage colony-stimulating factor (GM-CSF). Cloning and expression indicated that recombinant IRAP inhibited IL-I-induced adhesiveness of endothelial cells for neutrophils in vitro, IL-I augmentation of PHA-induced murine thymocyte proliferation, and IL-I stimulation of corticosterone production in mice in vivo (18) . An identical IL-I receptor antagonist protein was purified from the supernatants of four other human myelomonocytic cell lines after PHA-diMferentiation and GM-CSF stimulation: THP-I (19), H-161 (20) , , and HL-60 (20 (12) Lowering of insulin content in and decrease of insulin release from cultured rat pancreatic islet cells (13) under the influence of PMA and GM-CSF. What is the evidence that the IL-I inhibitory activity in human urine represents the same protein? This molecule was purified from the urine offebrile patients, although no amino acid sequence analysis was reported (21) . The urine-derived molecule demonstrated similar biological properties of an IL-I receptor antagonist as did the native or recombinant monocyte molecule. Furthermore, the urine molecule appeared to exist in a larger glycosylated form (21) . Lastly, antibodies specific for monocyte IL-Ira recognized the urine IL-I inhibitor (12 (14) smaller band of 15-16 kD, representing either a synthetic form or a product of proteolysis (22) . The heterogeneous 22-25 kD glycosylated forms predominated in monocyte supernatants over a small amount of nonglycosylated IL-Ira (22) . Human macrophages exhibited the same size distributions of IL-Ira in supernatants and lysates as described for monocytes (23) . IL-I ra is significantly conserved between species as the mouse and rat proteins are 77% and 75% identical, respectively, to the human protein (16) .
A structural variant of monocyte IL-Ira is present in keratinocytes and other epithelial cells (22) . This form of IL-Ira possessed the same 152-amino acid structure as mature monocyte IL-Ira but contained an additional seven residues at the NH2 terminus. The first four amino acids in this extension of keratinocyte IL-Ira were identical to the first four residues in the leader sequence of the synthesized monocyte form; however, the remaining three amino acids were different. The keratinocyte IL-Ira is probably encoded by the same gene as monocyte IL-Ira, with an alternative first exon spliced into an internal acceptor site between bp 87 and 88 ofthe monocyte cDNA (22) . Lacking a leader peptide, 18-kD keratinocyte IL-Ira remains almost completely intracellular and is not glycosylated (22, 24) . A smaller structural variant ofthe keratinocyte IL-Ira also may exist (22, 24) . The monocyte IL-Ira has been termed sIL-Ira (secretory) and the keratinocyte variant icIL-Ira (intracellular) (22) . However, the monocyte molecule, although possessing a leader peptide, is not completely secreted. Up to 50% of IL-Ira produced by monocytes remains cell-associated at any time during synthesis, while up to 80% of IL-Ira is found in the lysates of in vitro-derived macrophages (23) (30) . There are species differences, however, as human IL-Ira binds to murine type II IL-I receptors very weakly, if at all (14, 31) . These and other properties ofrecombinant IL-Ira are summarized in Table III. IL-Ira production The observation that the same population of human monocytes produces both the agonists IL-la and IL-IB as well as IL-Ira raises the question ofwhether production ofthese apparently opposing molecules is differentially regulated. That a single monocyte can synthesize both IL-I and IL-Ira simultaneously has not been proven, but would appear to be likely since myelomonocytic cell lines exhibit this capacity. During maturation of monocytes into macrophages IL-Il production is downregulated while IL-Ira production is greatly enhanced. Recent studies have clarified the mechanisms of regulation of production of IL-Ira by human monocytes. These studies have been aided by the development of a specific ELISA for IL-Ira, permitting quantification of this protein in fluids also containing IL-Ia or IL-IB (32) .
Stimulation of monocytes with LPS or culture on adherent IgG led to different patterns ofIL-I, or IL-I ra production (33) . LPS-stimulated monocytes produced near equal amounts of IL-1I, and IL-Ira protein over 24 h in culture with parallel IL-lI# and IL-lra production by monocytes (35) . The presence of 1% AB serum, soluble IgG, or GM-CSF all enhanced IL-lra production but not that of IL-lfi. In addition, nonadherent monocytes produced less IL-1ra but the same amounts of IL-1,B. The mechanisms responsible for this different, and possibly differential, regulation of IL-l,8 and IL-lra production by monocytes remain to be more completely determined. The mechanisms oftranscriptional regulation ofIL-I ra production by monocytes are being approached in ongoing studies (36). 1,680 bp of5'-flanking DNA forthe IL-lragene have been isolated, mapped, and sequenced. The results of initial studies indicate that DNA elements responsible for both baseline and LPS-induced expression ofIL-I ra are located in the most proximal 294 bp ofthe IL-lra promoter (36). Additional studies are necessary to delineate the specific DNA sequences that both bind regulatory proteins and exhibit function. A comparison will be made with similar studies being performed on regulation of IL-1,B transcription to explore whether a differential mechanism may exist.
What other stimuli induce IL-I ra production in monocytes and what other cells synthesize this protein has not yet been completely determined. As was observed with myelomonocytic cell lines, differentiation of human monocytes by PMA and/or GM-CSF enhanced IL-lra production (37, 38). Adherent monocytes differentiated in vitro into macrophages produced large amounts of IL-lra without any further stimulus (23) . Furthermore, these in vitro-derived macrophages were no longer responsive to LPS or to adherent IgG (23) . The results of recent studies indicate that IL-3 (39) and transforming growth factor ft (TGFB) (40) also induce IL-lra production in freshly isolated human monocytes. However, the presence of TGF, during monocyte differentiation into macrophages in vitro appears to downregulate IL-lra production (Lotz, M., and W. P. Arend, unpublished observations). The effects of other cytokines on monocyte production ofIL-1 ra remain to be systematically examined.
In addition to in vitro-derived macrophages, alveolar macrophages (AM) (41) and synovial tissue macrophages (42) also produced IL-lra. IL-lra production by AM was modestly enhanced by GM-CSF but, unlike peripheral monocytes, these cells failed to respond to LPS or adherent IgG (Janson, R. W., and W. P. Arend, unpublished observations). Thus, during differentiation from monocytes into macrophages in vitro or in vivo, the ability of these cells to enhance IL-lra production after stimulation with LPS or adherent IgG has been lost. The mechanisms responsible for this alteration in cell function have not been established. AM obtained from patients with interstitial lung disease produced more IL-lra than AM from nonsmoking or smoking normal donors, suggesting that these cells may have been activated in vivo. Thus, IL-lra is a major product oftissue macrophages, particularly in disease states. Lastly, cultured human peripheral neutrophils also contained both mRNA and protein for IL-Ira at 5% of the amount per cell observed in monocytes (Malyak, M., and W. P. Arend, unpublished observations).
The production of IL-Ia and the variant IL-Ira by keratinocytes also appear to be regulated differently (24) . Keratinocytes produced 390 ng IL-Ira/mg total protein, nearly equivalent to IL-Ira production by monocytes (a 300 ng IL-Ira/mg total protein). During differentiation of keratinocytes by culture in increasing concentrations of Ca", IL-Ira production increased more than twofold while IL-Ia and IL-I production remained unchanged. During differentiation the ratio ofIL-Ira to IL-Ia in keratinocytes increased from 12 to over 25 (24) . Lastly, IL-Ira extracted from keratinocytes exhibited identical biological activity per weight in comparison to recombinant monocyte IL-Ira.
In vitro properties ofIL-ira
The effects of unpurified or purified preparations of native ILIra on blocking of various IL-I-induced cell responses have been summarized in Table I . Additional information about IL-Ira functions in vitro have resulted from studies using the recombinant IL-Ira molecule. Most of the inhibitory effects observed with native IL-Ira have been confirmed with the recombinant molecule, indicating that possible contaminants in the native IL-Ira preparations were not responsible for these observations.
One universal theme that has emerged from recent studies is that excess amounts of IL-Ira over IL-I must be present in various in vitro systems in order to yield 50% inhibition of IL-I-induced responses (43) (Table III) . This observation probably reflects the fact that occupancy of a small number of IL-I receptors on a target cell is sufficient to induce a complete biological response. Because of this exquisite sensitivity to tiny amounts of IL-i, excess amounts of the receptor antagonist must be present in order to flood the system. The ratio of ILIra to IL-I necessary to block 50% of IL-I responses in vitro varies between 10 in rheumatoid synovial cells to over 500 for IL-I-dependent cell lines such as DIO.G4. 1 and LBRM.33. This variation probably reflects both the relative affinities of these molecules for IL-I receptors on each target cell as well as the relative abilities ofthe cells to mount a biological response.
Another important observation is that human IL-Ira appears not to affect human T cell responses in vitro. In contrast to the results ofstudies with murine Th2 clones (44) , IL-Ira did not inhibit the proliferation of human peripheral blood T cells induced by mitogen, soluble antigens, or allogeneic determinants (45) . This result suggests that IL-I may not be a necessary accessory molecule for proliferation of human T cells in vitro. These in vitro experiments need to be confirmed by similar in vivo studies. If IL-Ira exhibits an absence of effects on human T and B cell responses in vivo, its usefulness as a therapeutic agent in human diseases may be enhanced.
In vivo effects ofIL-Ira As stated earlier in this review, one of the important unanswered questions about IL-I relates to its role in normal physiology. Although IL-I is produced by many cells in vitro, its true role in functioning of the intact organism remains unclear. A second unanswered question concerns the relevance of IL-I to pathophysiology of various diseases. IL-I is one of many cytokines possibly produced in excess in infectious, inflammatory, or autoimmune human diseases. Although IL-I certainly has the potential to mediate events of tissue destruction, its primary role in this regard has not been established. Because ofthe redundant and overlapping nature of the cytokine network, inhibition of IL-I effects in vivo may not be sufficient to alter disease processes. The availability of recombinant IL-lra allows these important questions to be examined, first in animal models of disease and ultimately in human diseases.
The possible role of various cytokines and their inhibitors or antagonists in rheumatoid arthritis has recently been reviewed (46, 47) . In recent in vitro studies, IL-Ira blocked IL-Iinduced degradation ofproteoglycans and inhibition ofglycosaminoglycan synthesis in bovine nasal cartilage explants (48). In addition, rabbits given an intraarticular injection of IL-1,8 and then an intravenous injection of IL-Ira exhibited decreased leukocyte migration into the inflamed joint and reduced proteoglycan release from the articular cartilage (49) . Lastly, IL-Ira blocked type II collagen-induced arthritis in mice but not antigen-induced arthritis (50) . These results indicate that IL-Ira may modify some animal models of acute arthritis but not others, suggesting some variation in a possible primary role for IL-I in these disease models.
Unfortunately, no animal model of arthritis exactly resembles RA, primarily in the waxing and waning nature and chronicity of the human disease. Therefore, there is no substitute for direct observations on the human disease. IL-Ira was found in the urine of children with juvenile RA, particularly during periods of fever (51). One-half or more of patients with active RA exhibited high synovial fluid levels ofIL-Ira in the absence of detectable IL-1I3 (52) . In addition, IL-I ra mRNA was present in RA tissues, both in synovial lining cells and in perivascular lymphoid aggregates, and IL-Ira protein was produced by cultured synovial tissue cells (42) . The relevance ofthese observations to the pathophysiology of RA, or to the possible therapeutic application of IL-Ira in this disease, remains unclear. IL-Ira in rheumatoid synovial fluid may not influence events in the tissue at the pannus-cartilage interface.
Both tumor necrosis factor a (TNFa) and IL-I have been incriminated as mediators of inflammation in septic shock. The results of recent studies on the effects of IL-Ira in animal models of this disease suggest that IL-I may play a primary role. IL-Ira coinjected with LPS or IL-I into the trachea ofrats reduced the acute inflammatory response; moreover, LPS injected alone led to endogenous IL-Ira mRNA production by the lung (53). IL-Ira also blocked LPS-induced colony-stimulating factor production and early endotoxin tolerance in mice (54) . Three recent studies showed ameliorative effects ofIL-Ira in septic shock in rabbits (55, 56) or mice (57) . Fig. 1 reproduces data from reference 55 indicating the marked improvement in mortality from endotoxin-induced shock in rabbits after administration ofIL-I ra. What was not established by any of these studies was how long after induction of septic shock IL-Ira could be administered and beneficial effects still be seen. Endotoxin injection of normal volunteers led to the appearance of circulating IL-I inhibitor bioactivity (58) (61) . These fascinating observations suggest that the balance between IL-I and IL-lra may influence central nervous system events in vivo.
The skin represents another organ where some information exists on the presence of IL-1 and IL-lra, although functional relevance remains unclear. Cultured keratinocytes synthesized large amounts of precursor 31-kD IL-la and 18-kD IL-lra, both of which remained intracellular (24) . In recent studies IL-1 ra was found in large amounts in extracts of normal skin, in 100-fold higher concentrations than IL-la (62) . The ILlra was concentrated in the stratum granulosum of normal skin, consistent with the presence of more differentiated cells. Interestingly, IL-lra levels were slightly lower in skin lesions of psoriasis patients but IL-I a levels decreased more dramatically so that the ratio of IL-lra to IL-la in psoriatic skin exceeded 1,000 (62) . This alteration in cytokine production in psoriatic skin may play a primary role in the abnormal differentiation of epithelial cells in this disease.
Summary
This review has summarized recent information derived from many laboratories on the discovery, characteristics, and properties of a new member of the IL-I family, IL-receptor antagonist. In addition to information, an emphasis has been placed on unanswered questions and new concepts. The existence of this first-described naturally occurring specific cytokine receptor antagonist may lead to a different perspective on the cytokine network.
A major unanswered question emphasized throughout this review, that now can be addressed more directly, concerns what are the physiological roles ofmembers ofthe IL-I family. Although IL-Ij is presumed to function primarily as an extracellular cytokine, this molecule lacks a leader peptide, is synthesized and handled by the cells in a manner suggestive of a cytoplasmic (not secretory) protein (63) , and may only be released after cellular injury (64) . Furthermore, although IL-lra possesses a leader sequence, 50% or more of this protein remains cell associated. Do these observations suggest that members of the IL-l family possess important intracellular functions, as yet undetermined? IL-la may play an intracellular role in regulating senescence; an IL-a antisense oligodeoxynucleotide was shown to prolong the life span of cultured human endothelial cells (65 
